Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study

J Dermatol. 2024 Jan;51(1):135-139. doi: 10.1111/1346-8138.16990. Epub 2023 Oct 5.

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive, muscle-wasting disease. Notably, several extramuscular manifestations and complications of advanced DMD, including skin disorders, are known. However, hyperhidrosis and its treatment have not been well-described in association with advanced DMD, therefore we aimed to confirm the efficacy of 5% sofpironium bromide gel in treating secondary hyperhidrosis in patients with advanced DMD. We retrospectively reviewed patients with advanced DMD who underwent treatment with 5% sofpironium bromide gel. All patients were evaluated using the hyperhidrosis disease severity scale (HDSS) score and by measuring the gravimetric weight of palmar and/or plantar sweat. Three patients with advanced DMD were treated and the patients were aged 28, 31, and 32 years, respectively. Their HDSS scores showed a decreasing tendency within 5 weeks after treatment. In addition, all patients had a decreased gravimetric weight of palmar and/or plantar sweat, and the mean decrease rate of palmar sweat at 7 weeks after treatment was 53.7%. One patient had skin dryness on both soles, but no serious adverse events were observed. Treatment using 5% sofpironium bromide gel showed beneficial efficacy against palmoplantar hyperhidrosis in patients with advanced DMD. These findings warrant further investigation in future studies.

Keywords: 5% sofpironium bromide gel; Duchenne muscular dystrophy; extramuscular manifestations; hyperhidrosis; hyperhidrosis disease severity measure scale score.

MeSH terms

  • Bromides
  • Humans
  • Hyperhidrosis* / drug therapy
  • Muscular Dystrophy, Duchenne*
  • Retrospective Studies

Substances

  • Bromides

Supplementary concepts

  • Hyperhidrosis Palmaris Et Plantaris